Syncom Formulations (India) working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
66.90×66.90×37.06×49.19×54.61×
81.35×81.35×82.75×123.89×122.90×
75.23×75.23×39.75×51.87×52.67×
73.02×73.02×80.06×121.21×124.84×
2.20×2.16×2.21×1.57×3.27×
1.03×1.03×1.14×0.67×0.59×
0.76×0.76×0.47×−0.24×0.52×
0.75×0.75×0.43×−0.20×0.54×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNCOMF₹21.20

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,993 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)54.6149.1937.0666.9066.90
Receivable Days (DSO)122.90123.8982.7581.3581.35
Payable Days (DPO)52.6751.8739.7575.2375.23
Cash Conversion Cycle (days)124.84121.2180.0673.0273.02
Working Capital Turnover3.271.572.212.162.20
Asset Turnover0.590.671.141.031.03
Cash Conversion (CFO/Net Income)0.52-0.240.470.760.76
CFO/EBITDA0.54-0.200.430.750.75
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.